Cytokines in Hemopoiesis, Oncology, and AIDS

Front Matter....Pages i-lvii
Front Matter....Pages 1-1
Colony Stimulating Factors:Past and Future....Pages 3-7
Regulation of Hematopoietic Progenitor Cell Growth by Stimulating and Suppressing Cytokines....Pages 9-13
Cytokine Interactions in Normal and Malignant Hematopoiesis....Pages 15-25
Front Matter....Pages 27-27
Screening the Sensitivity of Hematopoietic Progenitor Cells to Different Growth Factors. Potential Importance in Therapy Trials with Colony Stimulating Factors....Pages 29-36
Effect of Human Recombinant Interleukin-3 in Long-term Bone Marrow Culture....Pages 37-44
Secretion of Colony-Stimulating Factor for Macrophages (M-CSF) and Granulocyte/Macrophages (GM-CSF) is Developmentally Regulated in Human Macrophages....Pages 45-51
Expression of the M-CSF/CSF-1 Gene in Normal Human Alveolar Macrophages....Pages 53-58
Surface Expression of Interleukin-2 Receptors and CD4 Molecules by Human Eosinophils is Induced by GM-CSF and IL-3....Pages 59-65
Expression of Interleukin Receptors on Human Eosinophils, Basophils, and Mast Cells....Pages 67-71
Chemiluminescence of Polymorphonuclear Leukocytes in Response to Interferons....Pages 73-80
Glycolysis and Amino Acid Incorporation in IL-3-Dependent Cell Lines....Pages 81-83
Fibroblast Colony Stimulating Activity of GM-CSF and IL-3 in Human Bone Marrow Cell Cultures....Pages 85-89
Chromatin and DNA Methylation Changes of the Human Myeloperoxidase Gene During Myeloid Differentiation....Pages 91-101
Retroviral-Mediated Transfer of Genes Encoding for Growth Factors into Human Hematopoietic Stem Cells....Pages 103-106
Recruitment Therapy in Acute Myeloblastic Leukemia:A Different Approach to Improved Leukemia Treatment....Pages 107-113
Effects of Hematopoietic Growth Factors on Myelodysplastic Syndrome Progenitors....Pages 115-122
Combined Cytogenetic and Proliferation Studies of GM-CSF-Stimulated Bone Marrow Cells in Myelodysplasia and Acute Leukemia....Pages 123-128
Recombinant Haemopoietic Factors (IL-3, IL-4, GM-CSF) Fail to Induce the Expression of Leucocyte Adhesion Receptors on Leukaemia Myeloid Colonies....Pages 129-134
In Vitro Evaluation of Antiproliferative Activity of CCRF-CEM Supernatant on Lymphoid and Nonlymphoid Leukemic Cells....Pages 135-140
TNF-α, IL-6, and Phorbol Ester but Not G-, M-, GM-CSF, IL-3, and IL-4, Induce Monocytic Differentiation and Modulate Expression of c-fos, c-fms , and c-myc in the Human Monoblast Line THP-1....Pages 141-148
Front Matter....Pages 27-27
In Vitro and In Vivo Inhibitory Effects of Interferon α 2b on CML Granuloerythroid Precursors....Pages 149-155
Several Cytokines Do not Influence Activity of P210 BCR-ABL Kinase in K562 Cells....Pages 157-162
Target Cell Specificity of Hematopoietic Growth Factors....Pages 163-171
Growth Factor-Dependent Stimulation of Primary Human Tumor Cells....Pages 173-180
Stimulation of Colony Formation of Various Human Carcinoma Cell Lines by rhGM-CSF and rhIL-3....Pages 181-187
Effects of Recombinant Cytokines on Clonogenic Cells from Primary Human Tumors....Pages 189-195
Mechanisms of TNF Action: Analysis of Receptor Structure and of Regulatory Circuits Controlling Receptor Expression and TNF Production....Pages 197-204
Synergism of Lymphotoxin and Interferon-γ in the Growth Inhibition of Breast Cancer Cell Line MCF-7....Pages 205-210
In Vitro Effect of Human Interferon-Gamma on Sister Chromatid Exchange Frequency and Proliferation of Cultured Human Amniotic Fluid Cells....Pages 211-216
Tumor Necrosis Factor/Cachectin Production by B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Cells....Pages 217-221
Activation of Cytolytic Effector Cells....Pages 223-226
Regulatory Effect of Recombinant Cytokines on NK Cell Differentiation from Early Marrow Precursors....Pages 227-236
Human NK Clones Regulate B-cell Development by Release of IFN-γ and TNF-α....Pages 237-243
Expression of High Affinity IL-2 Receptors on a Hodgkin Cell Line....Pages 245-252
Autologous Antileukemia Cytotoxicity Induced by PBL and BM Culture with rIL-2: Use in Autologous BMT for Inducing GVL?....Pages 253-262
Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines....Pages 263-270
Interleukin-2 (IL-2) in Acute Leukemia: In Vitro Studies and Possible Clinical Applications....Pages 271-276
Front Matter....Pages 277-277
Interleukin-1-α as a Modulator of Cytotoxic Drug Activity Against Human Cancer Cells....Pages 279-286
Biological Properties of Human Interleukin-4....Pages 287-291
Interleukin-6 (IL-6)/B Cell Stimulatory Factor 2-Dependent Growth of a Human IGA 2 /к-Myeloma Cell Line....Pages 293-298
Front Matter....Pages 277-277
Purification of a Mast Cell Growth-Enhancing Activity (MEA) Derived from a Murine Interleukin-2-Dependent, Mls a -Specific T Cell Line....Pages 299-304
Mast Cell Growth-Enhancing Activity (MEA) is a Potent Inducer of Interleukin-6 Production in a Murine Interleukin-3-Dependent Mast Cell Line....Pages 305-309
Monocyte-Conditioned Medium Factor as Auto-activation Signal for Monocyte Tumor Cytotoxicity....Pages 311-318
A Lymphokine Distinct from IL-2 and IL-4 with Proliferative Activity for a CD4 + T Cell Clone is Preferentially Produced by T H 2 Cells....Pages 319-329
Leukoregulin Enhancement of Tumor Inhibitory Drug Uptake....Pages 331-336
Increased Release of Cytokines from Human Peripheral Blood Mononuclear Cells by the β-Galactoside-Specific Lectin from Clinically Applied Mistletoe Extract....Pages 337-341
In Vitro Immunomodulatory Effects of the Thrombocytic Protein C 24....Pages 343-350
Degree of O - and N -Glycosylation of Lymphokines Released from A 23187-/TPA-Induced Lymphocytes Varies Differently with Culture Time....Pages 351-358
Phorbol Myristate Acetate and Calcium Ionophore A23187 Induce Two Waves of Lymphokine mRNA Transcription in Stimulated Human Peripheral Blood Lymphocytes....Pages 359-363
Comparison of the Engraftment Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation....Pages 365-372
Front Matter....Pages 373-373
Hematopoietins as Adjuvant Therapy in Cancer Patients....Pages 375-386
Effect of Chemotherapy Followed by GM-CSF for Acute Leukemias at Higher Age or After Relapse....Pages 387-401
Growth Response of Acute Myeloid Leukemic Blasts to GM-CSF In Vitro and In Vivo — Observations in One Patient....Pages 403-409
Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor After Autologous Bone Marrow Transplantation....Pages 411-417
Recombinant Human GM-CSF for Large-Scale Collection of Circulating Hematopoietic Progenitors in Cancer Patients Treated with High-Dose Cyclophosphamide....Pages 419-425
Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor for the Mobilization of Hemopoietic Progenitors Prior to Autologous Peripheral Blood Stem Cell Transplantation....Pages 427-432
Granulocyte Colony-stimulating Factor:Preclinical and Clinical Effects....Pages 433-447
Biology and Clinical Applications of Human Granulocyte Colony-Stimulating Factor....Pages 449-457
In Vivo Evaluations of Recombinant Human Macrophage Colony-stimulating Factor....Pages 459-468
The In Vivo Effects of IL-3 and GM-CSF in Primates....Pages 469-474
Front Matter....Pages 373-373
IL-3-Enhanced EPO Effects in Subhuman Primates....Pages 475-481
Use of Recombinant Human Erythropoietin after Bone Marrow Transplantation....Pages 483-487
The Effect of Erythropoietin on Neutrophil Production from Fetal Hematopoietic Progenitors....Pages 489-493
Response of Premature Anemic Infants to Subcutaneous Recombinant Erythropoietin....Pages 495-504
Interferon-α 2b as Therapy for Untreated and Pretreated Patients with Ph 1 Positive Chronic Myelogenous Leukemia....Pages 505-513
Interferon-α 2b in Chronic Myelogenous Leukemia: Experience with Two Treatment Regimen....Pages 515-524
Heterogenous Progenitor Sensitivity to Various Cytokines in Patients with Myeloproliferative Disorders; Correlation of In Vitro Interferon-α Sensitivity with the Clinical Responsiveness to Recombinant Interferon-α....Pages 525-537
Influence of Busulfan or Interferon-α Treatment on CFU-C from Bone Marrow and Peripheral Blood in Patients with CML in Chronic Phase....Pages 539-542
Incomplete Stroma Formation by Bone Marrow from Chronic Myeloid Leukemia Patients Treated with Interferon....Pages 543-550
Polymerase Chain Reaction for the Detection of Chimeric BCR/ABL mRNA in Patients with Chronic Myelogenous Leukemia (CML) — Detection of Minimal Residual Leukemic Cells After Bone Marrow Transplantation....Pages 551-559
Interferon-α in the Treatment of Chronic Myeloproliferative Disorders with Thrombocytosis....Pages 561-568
Recombinant Interferon-α, but not Interferon-γ, is Effective Therapy for Essential Thrombocythemia....Pages 569-574
The Role of Interferon-α 2 (IFN-α 2 ) in the Treatment of Low-Grade Non-Hodgkin’s Lymphoma. Preliminary Results of a Randomized Study:IFN-α 2 Plus Chlorambucil Versus Chlorambucil Alone....Pages 575-581
Evaluation of Myelotoxic Effects in Non-Hodgkin’s Lymphomas Treated with Interferon-α and Chlorambucil....Pages 583-587
Response of Early Stage B-CLL to Interferon-α:2 Years Experience of a Pilot Study....Pages 589-600
Successful Treatment of Angioimmunoblastic Lymphadenopathy (AIL) and B Cell Prolymphocytic Leukemia (B-PLL) with Interferon-α....Pages 601-606
Interferon Treatment of Neuroendocrine Gut and Pancreatic Tumors....Pages 607-613
Interferon-α 2b in Patients with Endocrine Active Tumors....Pages 615-624
Recombinant Interferon-α 2b in Patients with Advanced Osteosarcoma After Aggressive Chemotherapy....Pages 625-629
HIV-Associated Kaposi’s Sarcoma Treated with Recombinant Interferon-α 2a — Long-term Results....Pages 631-637
Front Matter....Pages 373-373
Acute Effects of Recombinant IFN-γ on White Blood Cell Counts and Lymphocyte Subsets in the Peripheral Blood of Cancer Patients....Pages 639-644
Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer....Pages 645-651
Increase of TNF-α Serum Levels in Major Transplant-Related Complications of Human Bone Marrow Transplantation— Association with Acute Graft-Versus-Host Disease and Activation of Host Macrophages....Pages 653-660
IL-2 and Cellular Therapy:Lymphokine-Activated Killer Cells and Tumor-Derived Activated Cells....Pages 661-671
Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies....Pages 673-681
rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma....Pages 683-690
Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT....Pages 691-697
IL-2 Treatment in a Patient with Stage IV Neuroblastoma After Allogeneic Bone Marrow Transplantation....Pages 699-705
Regional Adoptive Immunotherapy for Hepatic Metastasis....Pages 707-711
Adoptive Immunotherapy with IL-2 in 27 Patients with Metastatic Renal Cell Carcinoma....Pages 713-720
Adoptive Immunotherapy of Advanced Cancer with LAK Cells and Different Dosages of Interleukin-2:Analysis of Lymphocyte Subpopulations....Pages 721-727
Natural Interleukin-2 plus Lymphokine-Activated Killer Cells in Patients with Advanced Malignancy....Pages 729-733
Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells....Pages 735-741
Immunological Monitoring of Cancer Patients During a Phase I/II Clinical Trial of Natural Interleukin-2....Pages 743-749
Antibodies to Interleukin-2 (IL-2) in Patients: Cross Reactivity with Different IL-2 Species....Pages 751-756
Back Matter....Pages 757-762